Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology

BOCA RATON, Fla., May 7, 2013 /PRNewswire/ -- TriMix Laboratories, LLC and KRS Global Biotechnology, INC today announced the availability of TriMix-gel® in a 2000 microgram dose.  The joint developmental effort is the result of physicians and patients asking if it was possible for TriMix-gel to come in an increased dosage.  After development and testing, the new dosage is available immediately from KRS Global Biotechnology on the prescription of a licensed physician. 

TriMix-gel was introduced at the American Urological Association's World Conference.  Since then, thousands of American physicians have prescribed TriMix-gel for patients who cannot tolerate self-injection with a needle or who failed on PDE5 Inhibitors such as Viagra, Levitra or Cialis (J. Urol. 179 (4): 431, 2008).

Each individual dose of TriMix-gel is shipped to the patient in an ED-GEL™ applicator.  This novel, patent pending applicator, stores, mixes and applies the medicine without the patient having to self-inject himself with a needle.  Three short videos are available at www.TriMix-gel.com.  These videos are important in helping doctors and patients understand how to order TriMix-gel and how to apply the medicine.

TriMix Laboratories LLC develops innovative products toward the clinical advancement of urology.  For more information, visit www.TriMix-gel.com .  KRS Global Biotechnology is a recognized leader in pharmaceutical compounding, helping Physicians and Veterinarians with medicine precisely customized for each individual patient.  KRS maintains state licenses and dispenses compounded medications in almost all states. For more information, visit www.GBTBIO.com .

The information contained herein is general in nature and is intended for use only as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems. TriMix-gel has not been evaluated by the Food and Drug Administration (FDA) and is not made under GMP requirements. It is compounded in a licensed compounding pharmacy. The compound is for the use of an individual patient who has been prescribed TriMix-gel by a licensed physician.  The information contained herein is not intended for making an evaluation as to suitability, risks or benefits. Before taking any action, consult your Physician.

Contact: T.J. Harkins
TriMix Laboratories
800-572-3330

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE TriMix Laboratories

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED